Department of Neurosciences, University of Padova, Padova, Italy and IRCSS S. Camillo, Venice, Italy.
Clin Drug Investig. 2011;31(1):1-14. doi: 10.2165/11584740-000000000-00000.
Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease.
早期诊断和有效的治疗方法的出现，降低了重症肌无力（MG）以往高死亡率和严重残疾的负担。因此，MG 的预后现在有了很大的改善。然而，尽管对 MG 及其病因有了广泛的了解，但由于其非特异性和波动性症状，诊断该病仍然存在问题，并且可能会被延迟，MG 的治疗也存在相当大的局限性。目前基于免疫调节的治疗方法会产生长期免疫抑制引起的不良反应。需要提高初级护理人员对这种相对罕见但可治疗疾病的认识。
